Eyenovia Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 34
Employees
  • Stock Symbol
  • EYEN
Stock Symbol
  • Share Price
  • $4.63
  • (As of Monday Closing)

Eyenovia General Information

Description

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 295 Madison Avenue
  • Suite 2400
  • New York, NY 10017
  • United States
+1 (917) 000-0000

Eyenovia Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyenovia Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.63 $4.74 $2.55 - $7.72 $119M 25.8M 121K -$0.94

Eyenovia Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 128,504 128,504 58,315 11,643
Revenue 2,000 2,000 0 0
EBITDA (19,684) (19,684) (21,293) (17,237)
Net Income (19,770) (19,770) (21,157) (17,253)
Total Assets 33,907 33,907 14,698 20,015
Total Debt 463 463 42 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eyenovia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eyenovia‘s full profile, request access.

Request a free trial

Eyenovia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriet
Therapeutic Devices
New York, NY
34 As of 2020
000.00
000000 - 000 000.00

000000 0

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labo
0000 00000000
Bedford, MA
000 As of 0000
00000
000000 - 000 00000

00000000

re eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offic
00000000000 0000000
San Diego, CA
000 As of 0000
00000
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyenovia Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocular Therapeutix Formerly VC-backed Bedford, MA 000 00000 000000 - 000 00000
0000000000 0000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
000000 00000000000 Formerly VC-backed Redwood City, CA 00 00000 000000 - 000 00000
0000000 000000 Venture Capital-Backed Saratoga, CA 0 00000 0000000000 0 00000
To view Eyenovia’s complete competitors history, request access »

Eyenovia Executive Team (5)

Name Title Board Seat Contact Info
Tsontcho Ianchulev MD Chief Executive Officer & Chief Medical Officer
John Gandolfo Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Earnest Mario Ph.D Director
Fred Eshelman Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

Eyenovia Board Members (8)

Name Representing Role Since
Anthony Sun MD Self Board Member 000 0000
Charles Mather Eyenovia Board Member 000 0000
Curt LaBelle Eyenovia Board Member 000 0000
Ernest Mario Ph.D Self Board Member 000 0000
Fred Eshelman Self Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Eyenovia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyenovia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eyenovia‘s full profile, request access.

Request a free trial